PMID- 19117960
OWN - NLM
STAT- MEDLINE
DCOM- 20090908
LR  - 20141120
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 2
DP  - 2009 Mar-Apr
TI  - Catheter-related thrombosis: biological and clinical evidence for risk with 
      currently available anticoagulants.
PG  - 183-96
LID - 10.1177/1076029608326752 [doi]
AB  - Anticoagulants used during percutaneous coronary intervention (PCI) should not 
      only prevent coronary events, but also minimize the risk of periprocedural 
      complications. Current anticoagulation therapies for PCI include unfractionated 
      heparin (UFH), enoxaparin, fondaparinux, and bivalirudin. UFH and enoxaparin have 
      good efficacy and safety profiles in PCI; furthermore, associated periprocedural 
      complications such as catheter thrombosis are rare. Although newer anticoagulants 
      seem safe and effective in patients with acute coronary syndrome, clinical trial 
      data suggest that some pure factor Xa (FXa) inhibitors are associated with 
      increased rates of catheter thrombosis, compared with heparin-based agents. 
      Experimental systems show that polytherapeutic agents, including UFH and 
      enoxaparin, are more effective anticoagulants than certain single-target agents. 
      More studies are needed to assess whether catheter thrombosis is a class-, drug-, 
      or dose-related effect, and how best to prevent it. Future trials should report 
      the rates of periprocedural complications when assessing the safety of novel 
      anticoagulation therapies in PCI.
FAU - Montalescot, Gilles
AU  - Montalescot G
AD  - Institut de Cardiogie, Centre Hospitalier Universitarie Pitie-Salpetreire, Paris, 
      France. gilles.montalescot@psl.ap-hop-paris.fr
FAU - Walenga, Jeanine M
AU  - Walenga JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Anticoagulants/*administration & dosage
MH  - Factor Xa Inhibitors
MH  - Fibrinolytic Agents/administration & dosage
MH  - Heparin/administration & dosage
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Venous Thrombosis/*etiology
EDAT- 2009/01/02 09:00
MHDA- 2009/09/09 06:00
CRDT- 2009/01/02 09:00
PHST- 2009/01/02 09:00 [entrez]
PHST- 2009/01/02 09:00 [pubmed]
PHST- 2009/09/09 06:00 [medline]
AID - 1076029608326752 [pii]
AID - 10.1177/1076029608326752 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Mar-Apr;15(2):183-96. doi: 
      10.1177/1076029608326752.